Remeron (Mirtazapine) for Major Depressive Disorder
Remeron (mirtazapine) is FDA-approved for treating major depressive disorder in adults, with a starting dose of 15 mg once daily at bedtime, titrated up to a maximum of 45 mg daily based on response. 1
Indications
Mirtazapine is indicated specifically for major depressive disorder (MDD) in adults 1. The drug has demonstrated particular utility in patients with:
- Depression accompanied by anxiety symptoms
- Insomnia and sleep disturbance
- Poor appetite or weight loss requiring improvement 2
Recent evidence confirms mirtazapine's effectiveness extends to MDD patients with comorbid insomnia, showing 62.4% remission rates for insomnia and 41.3% for depression by 6 weeks 3.
Dosing Guidelines
Standard Adult Dosing
- Starting dose: 15 mg once daily, preferably in the evening before sleep
- Titration: May increase in increments every 5-7 days based on therapeutic response
- Typical effective dose: 15-45 mg/day
- Maximum dose: 45 mg once daily 1, 2
The orally disintegrating tablet (REMERONSolTab) should be administered immediately after removal from the blister pack 1.
Elderly Dosing
For elderly patients, start at 7.5 mg at bedtime with a maximum of 30 mg at bedtime 2. This lower dosing reflects the increased sensitivity of older adults to mirtazapine's sedative effects and potential for drug interactions. Elderly patients are preferred candidates for mirtazapine over paroxetine and fluoxetine due to better tolerability profiles 4. Studies in nursing home residents (mean age >70 years) used mean doses of only 19.4 mg/day with good efficacy 5.
Dose Adjustments
- Hepatic impairment: Use with caution; dose reduction may be needed 1
- Renal impairment (moderate to severe): Dose reduction may be necessary 1
- With strong CYP3A4 inhibitors: Decrease mirtazapine dose 1
- With strong CYP3A4 inducers: May need to increase mirtazapine dose 1
- With cimetidine: Dose reduction may be needed 1
Treatment Duration and Monitoring
Acute Phase
- Initial assessment: Monitor within 1-2 weeks of starting therapy for suicidal thoughts, agitation, irritability, or unusual behavioral changes 6
- Response evaluation: Assess therapeutic response at 6-8 weeks; if inadequate, modify treatment 6
- Full therapeutic trial: Requires at least 4-8 weeks 2
Continuation Phase
Continue treatment for 4-9 months after achieving satisfactory response in first-episode MDD 6. This prevents relapse during the continuation phase.
Maintenance Phase
For patients with 2 or more depressive episodes, consider years to lifelong therapy 6. The risk of recurrence justifies extended treatment in recurrent depression.
Contraindications
Absolute contraindications:
- Concomitant use with MAOIs or within 14 days of stopping MAOIs (risk of serotonin syndrome) 1
- Known hypersensitivity to mirtazapine or any excipients 1
Tapering Recommendations
Discontinue mirtazapine gradually over 10-14 days to limit withdrawal symptoms 2, 1. Abrupt discontinuation should be avoided. After 9 months of treatment, consider dosage reduction to reassess the ongoing need for medication 2.
Key Warnings and Precautions
Black Box Warning
Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients. Close monitoring is mandatory, especially during the first 1-2 months of treatment when suicide risk is highest 6, 1.
Serious Adverse Effects to Monitor
- Agranulocytosis: If sore throat, fever, stomatitis, or infection signs occur with low WBC, discontinue immediately 1
- Serotonin syndrome: Risk increases with co-administration of other serotonergic drugs (SSRIs, SNRIs, triptans). Discontinue if suspected 1
- QT prolongation: Use cautiously in patients with risk factors 1
- DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): Discontinue if suspected 1
- Angle-closure glaucoma: Can occur in patients with untreated narrow angles 1
Common Adverse Effects
The most common adverse effects (≥5% and twice placebo rates) include:
- Somnolence (12-62% in various studies)
- Increased appetite and weight gain (mean 1.3 kg by 6 weeks)
- Dry mouth
- Dizziness 1, 5, 3
Notably, mirtazapine does NOT cause sexual dysfunction, unlike SSRIs 7, making it advantageous for patients concerned about this side effect.
Additional Precautions
- Hyponatremia: Monitor, especially in elderly patients 1
- Seizures: Use cautiously in patients with seizure disorders 1
- Mania/hypomania activation: Screen for bipolar disorder before initiating 1
- Elevated cholesterol/triglycerides: Has been reported 1
- Transaminase elevations: Monitor in hepatic impairment 1
Clinical Advantages
Mirtazapine offers several unique benefits:
- Rapid onset: Evidence suggests faster improvement than SSRIs, with benefits visible at weeks 1-2 compared to SSRIs 8
- Sleep promotion: Potent sedative effects beneficial for insomnia 2
- Appetite stimulation: Useful when weight gain is desired 2
- No sexual side effects: Unlike SSRIs 7
- Low drug interaction potential: Minimal effects on CYP2D6 metabolism 8, 7
Drug Interactions
Monitor INR when co-administering with warfarin 1. The drug has low potential for clinically significant interactions due to minimal CYP2D6 inhibition, making it suitable for patients requiring polytherapy 8, 7.